Cargando…

A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS

BACKGROUND: Cirrhosis is associated with immune dysfunction, which increases susceptibility to infection and subsequent hospitalization. Vaccination of this high-risk patient population can mitigate the risk of infection. AIMS: Data from the National Inpatient Sample (NIS) was analyzed to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudson, D, Khanna, R, Brahmania, M, Qumosani, K, Teriaky, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859187/
http://dx.doi.org/10.1093/jcag/gwab049.224
_version_ 1784654399756304384
author Hudson, D
Khanna, R
Brahmania, M
Qumosani, K
Teriaky, A
author_facet Hudson, D
Khanna, R
Brahmania, M
Qumosani, K
Teriaky, A
author_sort Hudson, D
collection PubMed
description BACKGROUND: Cirrhosis is associated with immune dysfunction, which increases susceptibility to infection and subsequent hospitalization. Vaccination of this high-risk patient population can mitigate the risk of infection. AIMS: Data from the National Inpatient Sample (NIS) was analyzed to compare the prevalence of vaccine-preventable diseases (VPD) among hospitalized patients both with and without cirrhosis. METHODS: The 2013 NIS database was interrogated using ICD-9-CM codes to identify patients with cirrhosis and VPD. Baseline characteristics were compared (see: Table 1). Univariate and multivariate regression models identified risks associated with VPD adjusting for survey procedures. RESULTS: 313,710 patients were hospitalized for VPD, including 13,080 patients (4.1%) with cirrhosis (see: Table 1) Patients with cirrhosis were more likely to be hospitalized with pneumococcal pneumonia (odds ratio [OR] = 1.45 [95% CI 1.29 – 1.63], P <0.001), hepatitis A (OR = 7.04 [95% CI 5.96 – 8.31], P <0.001) and hepatitis B (OR = 14.41 [95% CI 12.53 – 14.36], P <0.001) infections compared to patients without liver cirrhosis. Patients with cirrhosis were less likely to have an infection with influenza (OR = 0.55 [95% CI 0.49 – 0.62], P <0.001), human papillomavirus (HPV) (OR = 0.57 [95% CI 0.43 – 0.75, P < 0.001) and varicella zoster (OR = 0.78 [95% CI 0.69 – 0.89], P <0.001). Minimal differences in hospitalizations for haemophilus influenzae or meningococcal infections were noted between groups. Odds ratios for VPD adjusting for age, sex, race, patient location, patient income, hospital type and bed-size, mortality risk, type 2 diabetes mellitus, malignancy, human immunodeficiency virus (HIV), organ transplantation and immunodeficiency: pneumococcal pneumonia (OR = 1.27 [95% CI 1.13 – 1.44], P < 0.001), hepatitis A (OR = 5.99 [95% CI 5.02 – 7.15], P < 0.001); and hepatitis B (OR = 11.07 [95% CI 10.24 – 11.97], P < 0.001). CONCLUSIONS: These results emphasize the importance of vaccinating patients with cirrhosis against pneumococcal pneumonia, hepatitis A and hepatitis B infections to reduce hospitalization [Image: see text] Table 1: Baseline characteristics of patients with cirrhosis and without cirrhosis presenting with a vaccine preventable disease. FUNDING AGENCIES: None
format Online
Article
Text
id pubmed-8859187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-88591872022-02-22 A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS Hudson, D Khanna, R Brahmania, M Qumosani, K Teriaky, A J Can Assoc Gastroenterol Poster of Distinction BACKGROUND: Cirrhosis is associated with immune dysfunction, which increases susceptibility to infection and subsequent hospitalization. Vaccination of this high-risk patient population can mitigate the risk of infection. AIMS: Data from the National Inpatient Sample (NIS) was analyzed to compare the prevalence of vaccine-preventable diseases (VPD) among hospitalized patients both with and without cirrhosis. METHODS: The 2013 NIS database was interrogated using ICD-9-CM codes to identify patients with cirrhosis and VPD. Baseline characteristics were compared (see: Table 1). Univariate and multivariate regression models identified risks associated with VPD adjusting for survey procedures. RESULTS: 313,710 patients were hospitalized for VPD, including 13,080 patients (4.1%) with cirrhosis (see: Table 1) Patients with cirrhosis were more likely to be hospitalized with pneumococcal pneumonia (odds ratio [OR] = 1.45 [95% CI 1.29 – 1.63], P <0.001), hepatitis A (OR = 7.04 [95% CI 5.96 – 8.31], P <0.001) and hepatitis B (OR = 14.41 [95% CI 12.53 – 14.36], P <0.001) infections compared to patients without liver cirrhosis. Patients with cirrhosis were less likely to have an infection with influenza (OR = 0.55 [95% CI 0.49 – 0.62], P <0.001), human papillomavirus (HPV) (OR = 0.57 [95% CI 0.43 – 0.75, P < 0.001) and varicella zoster (OR = 0.78 [95% CI 0.69 – 0.89], P <0.001). Minimal differences in hospitalizations for haemophilus influenzae or meningococcal infections were noted between groups. Odds ratios for VPD adjusting for age, sex, race, patient location, patient income, hospital type and bed-size, mortality risk, type 2 diabetes mellitus, malignancy, human immunodeficiency virus (HIV), organ transplantation and immunodeficiency: pneumococcal pneumonia (OR = 1.27 [95% CI 1.13 – 1.44], P < 0.001), hepatitis A (OR = 5.99 [95% CI 5.02 – 7.15], P < 0.001); and hepatitis B (OR = 11.07 [95% CI 10.24 – 11.97], P < 0.001). CONCLUSIONS: These results emphasize the importance of vaccinating patients with cirrhosis against pneumococcal pneumonia, hepatitis A and hepatitis B infections to reduce hospitalization [Image: see text] Table 1: Baseline characteristics of patients with cirrhosis and without cirrhosis presenting with a vaccine preventable disease. FUNDING AGENCIES: None Oxford University Press 2022-02-21 /pmc/articles/PMC8859187/ http://dx.doi.org/10.1093/jcag/gwab049.224 Text en ڣ The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster of Distinction
Hudson, D
Khanna, R
Brahmania, M
Qumosani, K
Teriaky, A
A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title_full A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title_fullStr A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title_full_unstemmed A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title_short A225 VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS WITH END-STAGE LIVER DISEASE/CIRRHOSIS: A NATIONWIDE COHORT ANALYSIS
title_sort a225 vaccine-preventable diseases in hospitalized patients with end-stage liver disease/cirrhosis: a nationwide cohort analysis
topic Poster of Distinction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859187/
http://dx.doi.org/10.1093/jcag/gwab049.224
work_keys_str_mv AT hudsond a225vaccinepreventablediseasesinhospitalizedpatientswithendstageliverdiseasecirrhosisanationwidecohortanalysis
AT khannar a225vaccinepreventablediseasesinhospitalizedpatientswithendstageliverdiseasecirrhosisanationwidecohortanalysis
AT brahmaniam a225vaccinepreventablediseasesinhospitalizedpatientswithendstageliverdiseasecirrhosisanationwidecohortanalysis
AT qumosanik a225vaccinepreventablediseasesinhospitalizedpatientswithendstageliverdiseasecirrhosisanationwidecohortanalysis
AT teriakya a225vaccinepreventablediseasesinhospitalizedpatientswithendstageliverdiseasecirrhosisanationwidecohortanalysis